Researchers from the Weizmann Institute of Science in Rehovot, Tel Aviv startup Pheno.AI, and chip giant NVIDIA have developed GluFormer, an artificial intelligence model that can predict an individual’s future glucose levels and other health metrics based on past glucose monitoring data.
The model was trained on 14 days of glucose monitoring data from more than 10,000 non-diabetic study participants, with data collected every 15 minutes through a wearable monitoring device. The data was collected as part of the Human Phenotype Project, an initiative by Pheno.AI, a startup that aims to improve human health through data collection and analysis.
GluFormer can currently predict the response of glucose levels to a person’s actions. For example, if they ate a certain meal under certain conditions, the model can show how each individual would respond.
The model can predict blood glucose levels up to four years in advance and compare results with or without a particular treatment in order to adapt a future treatment plan and help patients adhere to it. For pharmaceutical companies, the system can help predict clinical trial outcomes.
Other values that the model should be able to predict are: fatty tissue around the liver and pancreas, blood pressure and sleep apnea, through continuous monitoring of changes in the patient’s sugar levels and other medical tests.
The research is led by Professor Eran Segal of the Weizmann Institute’s Department of Computer Science and Applied Mathematics, Professor Gal Chechik, Senior Director of AI Research at Nvidia, Pheno.ai data researcher Gal Sapir, and principal investigator Jay Lutzker. Nvidia researcher and Ph.D. Student at the Weizmann Institute.
Published by Globes, Israel Business News – en.globes.co.il – on November 26, 2024.
© Copyright Globes Publisher Itonut (1983) Ltd., 2024.
Comments are closed, but trackbacks and pingbacks are open.